StreetInsider.com News Articles

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

The event will focus on the company's lead clinical program, IMNN-001, an IL-12 DNA plasmid immunotherapy being evaluated for the treatment of newly diagnosed advanced ovarian cancer. Presentations will cover the ongoing Phase 3 OVATION 3 trial and updates from the company's Phase 2 minimal residual disease trial, conducted in partnership with Break Through Cancer and led by researchers at The University of Texas MD Anderson Cancer Center.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to host R&D day on Phase 3 ovarian cancer trial in September

Wed, 26 Aug 2026 08:30:38 -0400

Imunon, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

Oncology

Imunon to hold R&D Day on Sept. 23 focused on ovarian cancer trial

Wed, 26 Aug 2026 08:30:25 -0400

Imunon, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announced it will host an R&D Day for investors, analysts, and media on September 23, 2026, at the Sofitel New York in New York City, beginning at 10:00 a.m. ET.

The event will focus on the company's lead clinical program, IMNN-001, an IL-12 DNA plasmid immunotherapy being developed for the treatment of advanced ovarian cancer. Presentations will cover progress in the ongoing pivotal Phase 3 OVATION 3 trial and upcoming milestones for the program.

Oncology experts and company management are scheduled to present. Topics will include data and science supporting IMNN-001, as well as

IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001

Wed, 26 Aug 2026 08:30:00 -0400

Leading oncology experts and company management will discuss the Phase 3 OVATION 3 study, supporting science and data, clinical progress, and upcoming milestones